This infographic highlights findings from our biopharma-partnering survey on the qualities that sell-side companies are looking for in a licensing partner and ranks the industry’s top-tier partners. For a more in-depth look at the survey findings, visit here: http://on.bcg.com/1tTRB3r.

1. Deals are heavily concentrated in a small
number of specialty therapeutic areas
(TAs), including oncology, inflammation,
neuroscience, and infectious diseases
Midsize oncology specialist Celgene
had the highest average score
across all attributes
It also received the most
nominations as “top partner”
and the widest recognition as
a good company to partner with
J&J, BMS, and Lilly joined—and
Merck and Roche remained in—
the top tier
Highest average score across all partnering
attributes (and change since 2012)
Study
Description
Focus on
Value Creation
Lessons for
Deal Makers
Licensing
today is
increasingly
competitive
Celgene
becomes the
top partner
of choice
Several
big pharma
companies rose
in the rankings
Partnership deals have decreased by
41% since 2010, driven primarily by
the favorable IPO market
Yet the average deal value has grown
by more than $100 million—or
nearly 60%—over the same period
Average up-front payments are also on
the rise—they’ve more than doubled
since 2010
BCG’s latest Biopharma Partnering Survey, our sixth in
12 years, examined licensing and business development
activity in the global biopharmaceutical industry. For
executives on either the buy side (licensees) or the sell side
(licensors), the survey remains the premier source of
information on licensing activity and sellers’ perceptions. The
2014 survey included responses from 63 senior executives
(including CEOs, presidents, and heads of business
development) across a range of biopharma firms worldwide.
Bigger Licensing Deals
Require Better Partners
Highlights from BCG’s 2014
Biopharmaceutical Partnering Survey
Partner that can add
value to their product/TA
(4.6 average importance)
Partnership that will
develop & prosper (4.5)
Dependable clinical
development
capabilities (4.4)
Global reach (4.2)
12 years of
surveys provide BCG
with a broad
perspective on
shiing perceptions
and priorities. Vast
structural changes
in health care, along
with the industry's
strong emergence
from the tumult of
2008-2010, have had
a profound effect on
the economics of
the industry, and in
turn, on licensing
partnership trends.
Key attributes that
sell-side companies
are looking for in
a partnership:
1
0
2
3
4
5
1 Celgene
2 Merck
3 J&J
4 Roche
5 BMS
6 Lilly
Read BCG’s latest insights, analysis, and viewpoints at bcgperspectives.com
© The Boston Consulting Group, Inc. 2015. All rights reserved.
To find the latest BCG content and register to receive e-alerts on this topic or others,
please visit bcgperspectives.com. Please direct questions to socialmedia@bcg.com.